ORF_ID	Contig	Start	Stop	Orientation	Cut_Off	Pass_Bitscore	Best_Hit_Bitscore	Best_Hit_ARO	Best_Identities	ARO	Model_type	SNPs_in_Best_Hit_ARO	Other_SNPs	Drug Class	Resistance Mechanism	AMR Gene Family	Predicted_DNA	Predicted_Protein	CARD_Protein_Sequence	Percentage Length of Reference Sequence	ID	Model_ID	Nudged	Note	Hit_Start	Hit_End	Antibiotic
BGC0000259.1|Prodigiosin_1 # 1 # 171 # 1 # ID=1_1;partial=10;start_type=Edge;rbs_motif=None;rbs_spacer=None;gc_cont=0.661	BGC0000259.1|Prodigiosin_1 	1	171	+	Loose	200	23.483	vanT gene in vanC cluster	56.25	3002970	protein homolog model	n/a	n/a	glycopeptide antibiotic	antibiotic target alteration	glycopeptide resistance gene cluster; vanT	ATCGGCACCCGCGCCACGCTGACGGAACCGATGCACAACGGCATGGGCCGCATCAATATCGGCGACAGCAGCTGGCGCGCGCAGGCGGCGGAAGATCTGCCTGCCGGCACTGAAGTGGAAGTGGTGGCGGTGGAAGGGGTCACGCTGGTGATCCGCGCCATCAGCCGTTAA	IGTRATLTEPMHNGMGRINIGDSSWRAQAAEDLPAGTEVEVVAVEGVTLVIRAISR	MKNKGIDQFRVIAAMMVVAIHCLPLHYLWPEGDILITLTIFRVAVPFFFMISGYYVFAELAVANSYPSRQRVFNFIKKQLKVYLLATLMFLPLALYSQTIGFDLPVGTLVQVLLVNGILYHLWYFPALITGSLLLTSLLIHVSFKKVFWLAAGLYLIGLGGDSWFGLIQQTPIEPFYTAVFHLLDGTRNGIFFTPLFLCLGVLVRKQSEKRSLSKTALFFLISLIGLLIESAYLHGFSIPKHDSMYLFLPVVLFFLFPLILRWHPHRTWKHPGQLSLWLYLLHPYTIAGTHFLSQKISILQNNLINYLVVLILTIGFICLFLRQKHSWFRHKQTTPVKRAVKEFSKTALLHNLQEIQRIISPKTKVMAVVKADAYGCGAKEVAPVLEQAGIDFFAVATIDEGIRLRKNAVKSPILVLGYTSPKRIKELRRYSLTQSIISEGHAVALSQRKVAIDCHLAIDTGMHRLGVTPTIDSILSIFDLPFLTISGVYSHLGSADRLNPDSMIRTQKQIACFDQILLELDQRQISYGITHLQSSYGILNYPDLNYDYVRPGILLTGSLSDTNEPTKQRVSLQPILTLKAQLITKRVVAKGEAIGYGQTAVANQETTVGVVSIGYCDGLPRSLSNQEFCLSYRGQSLPQIGLICMDMLLIDLSHCPTIPIESEIEILTDWSDTAEQVQTITNELICRIGPRVSARIK	8.02	gnl|BL_ORD_ID|4675|hsp_num:0	734			306	354	vancomycin
BGC0000259.1|Prodigiosin_2 # 168 # 602 # -1 # ID=1_2;partial=00;start_type=ATG;rbs_motif=AAG;rbs_spacer=7bp;gc_cont=0.579	BGC0000259.1|Prodigiosin_2 	168	602	-	Loose	290	82.4185	golS	34.11	3000504	protein homolog model	n/a	n/a	monobactam; carbapenem; cephalosporin; cephamycin; penam; phenicol antibiotic; penem	antibiotic efflux	resistance-nodulation-cell division (RND) antibiotic efflux pump	ATGAGCAGGAGCATTCCGGAGGAAAAAATGAATATTAGCGACGTCGCGAAAAAGACCGGGTTAACCAGCAAGACGATTCGTTTTTACGAGGAGAAAAGCGCTGATTACCCGGCCCCGATCCGCAGCGATAACGGTTATTGCCCATTATTCCCGCCAGGCACGTTGAAGAGTTGCACGCTGCTGCGCCAGGCGCGGCAGGTGGGCTTCAACCTGGACAAGTGCCGTGAGCTGGTGGCGTTATTCAACGATCCGGCCCGCCACAGCGCCGACGTGAAGGCGCGCACGCTGCAGAAGGTGGCGGAGATCGAAAGGCACATCAGCGAACTGGGAGAAATGCGCCAACGCCTGTTGACGCTGGCGGAACAATGTCCGGGCGACGAGGGGGCGGAGTGCCCCATCATCAATAATCTGGCGGGATGCTGTCGTTCGAATTAA	MSRSIPEEKMNISDVAKKTGLTSKTIRFYEEKSADYPAPIRSDNGYCPLFPPGTLKSCTLLRQARQVGFNLDKCRELVALFNDPARHSADVKARTLQKVAEIERHISELGEMRQRLLTLAEQCPGDEGAECPIINNLAGCCRSN	MNIGKAAKASKVSAKMIRYYEQIGLIPAASRTDSGYRAYTQADVNQLHFIRRARDLGFSVAEISDLLNLWNNQSRQSADVKRLAQTHIDELDRRIQNMQHMAQTLKALIHCCAGDALPDCPILHTLGQPDDSEPEARTGAVLRRPRRHGLAKRL	93.51	gnl|BL_ORD_ID|35|hsp_num:0	44			0	381	chloramphenicol
BGC0000259.1|Prodigiosin_3 # 773 # 898 # -1 # ID=1_3;partial=00;start_type=ATG;rbs_motif=AGG;rbs_spacer=7bp;gc_cont=0.183	BGC0000259.1|Prodigiosin_3 	773	898	-	Loose	880	23.483	arlS	32.0	3000839	protein homolog model	n/a	n/a	fluoroquinolone antibiotic; disinfecting agents and antiseptics	antibiotic efflux	major facilitator superfamily (MFS) antibiotic efflux pump	ATGGTAAATGTAAGTAAATGTTTATTTATGTGGTCTATTATTACAATTTTGTTAATTGATGTTTTTATTTTGTTGTTTTTGTTGTGTTTTATTTTGTGTTATTTATACACAAAAATTTACATATAA	MVNVSKCLFMWSIITILLIDVFILLFLLCFILCYLYTKIYI	MTKRKLRNNWIIVTTMITFVTIFLFCLIIIFFLKDTLHNSELDDAERSSSDINNLFHSKPVKDISALDLNASLGNFQEIIIYDEHNNKLFETSNDNTVRVEPGYEHRYFDRVIKKRYKGIEYLIIKEPITTQDFKGYSLLIHSLENYDNIVKSLYIIALAFGVIATIITATISYVFSTQITKPLVSLSNKMIEIRRDGFQNKLQLNTNYEEIDNLANTFNEMMSQIEESFNQQRQFVEDASHELRTPLQIIQGHLNLIQRWGKKDPAVLEESLNISIEEMNRIIKLVEELLELTKGDVNDISSEAQTVHINDEIRSRIHSLKQLHPDYQFDTDLTSKNLEIKMKPHQFEQLFLIFIDNAIKYDVKNKKIKVKTRLKNKQKIIEITDHGIGIPEEDQDFIFDRFYRVDKSRSRSQGGNGLGLSIAQKIIQLNGGSIKIKSEINKGTTFKIIF	9.09	gnl|BL_ORD_ID|165|hsp_num:0	182			27	96	ciprofloxacin; acriflavine; norfloxacin
BGC0000259.1|Prodigiosin_4 # 982 # 2139 # 1 # ID=1_4;partial=00;start_type=ATG;rbs_motif=GGA;rbs_spacer=7bp;gc_cont=0.572	BGC0000259.1|Prodigiosin_4 	982	2139	+	Loose	1050	28.8758	facT	27.06	3001313	protein homolog model	n/a	n/a	elfamycin antibiotic	antibiotic efflux	major facilitator superfamily (MFS) antibiotic efflux pump	ATGGATTTTAACTTATCAAGTGAGCAGCAGGCTCTAAGCGAATCCGCTCAGCGTTTTGCCCGCGAGGTGCTGGATCAGGATGCGCATGCTCGGCTTTCACGGCAGGTATTAAGCCTGGATTTGTGGCAACAAGCCGCCGCCTATGGTTTTACCCGAGCCCCCGTGACGACCGCGTTCGGCGGATTGGGCATGAATGCGCTCGATACTGCACTGATGATTGAGGCGCTGGGTAAAGGCAGCCGCGACATCGGCATGTCCTTCTCGCTCTGCGCCCATCTGTGCGCCTGCGTGATCCCGCTTTCCCGCTTCGGTTCCGAGGCATTAAAAGCGCGCTATCTCGAAGCGTTGGCGGCCGGAAAACTGATCGCGGCGAATGCGGCGACGGAGCCGGACGCCGGTTCCGATATTTATGCCATGAAATCAACCGCTCAACCCTGTGAAGGCGGCTACCGGCTCAACGGAAACAAAATTTTCATCACCAACGCGCCGATTGCCGACATCTTCATCGTCTATGCGAAAACCCATCCCGAACATGGCTTTATGGGCGTGTCCGCATTTGTGCTCGAGAAAGGGATGCCAGGCTTAAACGTAGGCGCCGTCAGCCCGAAAGATTGCCTCTCCAACTGCCCGTGGAGCGAACTGACCTTCAACGACGTCTTCATTCCAGAGACCCAACGGATCGGTATGCCGGGCGCCGGCGGCGCCATCTTCCACGATTCAATGATCTGGGAAAAGGGCTGCCTGTCGGCTCTGTTTATCGGCGCAATGGAGCGCGTGTTCGACAGCGCGCTGGACTATGCCAAACAACGCCGACAATTCGGCAAAGCGATCGGCCAATTTCAGTCCGTCTCCAACCGCATCATCGATATGAAACTGCGTCTGGAACAGTGTCGGCTAATGCTCTACCGCGCCTGTTGGAAACACGATCGGGGCCAGGATGCCGAGATCGACATCGCCATGAGCAAACTGTTGATTTCCGAATATGCCGTGCAGTCCGCGCTGGACGCGATTCAAATCTTCGGCGGAGCCGGCATGGATCAAGAACTCGGTCTGGTGCGCCACTTGCTGAACGTGATCCCCAGCCGGATCTTCTCCGGCACCAACGAGATACAAAAAGAAATTGTCGCCCGCAAGCTGGGTCTGCGGGGAGGCGCATGA	MDFNLSSEQQALSESAQRFAREVLDQDAHARLSRQVLSLDLWQQAAAYGFTRAPVTTAFGGLGMNALDTALMIEALGKGSRDIGMSFSLCAHLCACVIPLSRFGSEALKARYLEALAAGKLIAANAATEPDAGSDIYAMKSTAQPCEGGYRLNGNKIFITNAPIADIFIVYAKTHPEHGFMGVSAFVLEKGMPGLNVGAVSPKDCLSNCPWSELTFNDVFIPETQRIGMPGAGGAIFHDSMIWEKGCLSALFIGAMERVFDSALDYAKQRRQFGKAIGQFQSVSNRIIDMKLRLEQCRLMLYRACWKHDRGQDAEIDIAMSKLLISEYAVQSALDAIQIFGGAGMDQELGLVRHLLNVIPSRIFSGTNEIQKEIVARKLGLRGGA	MNKAGQAEKPAAAGPPATPETPEPDPKRWLALTVLLVATFMDLLDANIITVAIPSIQRDLGASTFAIQAMTAGYTLSFAVLLITGGRLGDIFGRKRMFLVGVGGFVLASAMCAAAPSTDLLVVARALQGLTAAVMVPQVLALIHVSFAPQEIGRVVSLYASMVGLAIVSGPLIGGALISWNPLDLGWRSIFVVNLPVGVLALVGAAKWMRESSSPHAKRLDIAGMLLIVLGLLLLMVPLTLGRELDWPVWSIVSLVAAAPVLVLFVVYERHKTAKDGSPLVTLSLFKVRAFGAGIGVQLLFSAIPAGFFLSWTLYLQAGLGWSALHTGLTAIPFSLCVPIVGGLAVRRLSPLYGRYCLLAGAVLMLAGILSYAWAADRFGTDITSWHAIPSMLLIGSGMGMLMPPLTALVLREVQPQEAGAASGIINATGQLGAALGVAVIGSLFFAALAGNAGPQAERVAPTVQSVSPRQASDLRDCATEALGQDDLAKVPDICSTLVQGADDGTRDTINGALGEIRAKTFVSTYSETLYWAAGGLVPVTALVLLLPHHRVRREEPAQ	68.87	gnl|BL_ORD_ID|1345|hsp_num:0	1469			105	333	factumycin
BGC0000259.1|Prodigiosin_5 # 2139 # 4151 # 1 # ID=1_5;partial=00;start_type=ATG;rbs_motif=AGG;rbs_spacer=6bp;gc_cont=0.594	BGC0000259.1|Prodigiosin_5 	2139	4151	+	Loose	600	31.5722	Streptomyces venezuelae rox	50.0	3007209	protein homolog model	n/a	n/a	rifamycin antibiotic	antibiotic inactivation	rifampin monooxygenase	ATGATCGTTCAACGCGTTTTTGCCGTGCTCTATATGTTGGCCGGCCTGGCGAAAGCCTTCCCTCAGTTGGAAAACGTCGCCGATATTCTGCAGCAGGCGGCCGTGGCGAACCAGGGCACCTGGTACGCCGGGGCGACGGCTTGGTTGGCGGCGCAAGGTACAGTGGTTAACGCGCTGATCGGCGTGGCGCTGTTTGCCTCCGGTGCGGTCTTGATGTTCAACCCGCGTTGGACGCCATTGATCATCTACTGCCAGCTGCTGATGATGGCGGGATTTGTCACGATCCTGCACCGCGCCCAGCCGCAGGTCATGTTGCTCGATGCGATTTTCGCGCTGGCGGCGCTGTACATGCTGCGTCAGCAGCACCACCGCAAACCCAAGCCGCGCACGTTCCCCACGCGCGACTTTTCCACGCCCACGCCGGCGGCAGGCGGCCCGGTAACCCCCGCGCTGGACGGCGAGTATGACGTGGTGATCATCGGCGGCGGCGTCTCCGGTTTGGCCGCGGCCAGCGAACTGACCGATCGCCGGGTTTTGGTGCTGGAAAAAAGCGCCTCCTTCGGCGGCAACGCCCGCTACAGTACGGTGAACCGCCTGAAATTTCCTATCGCCGGCGTCTGCTTCCAGGAACCGCTGCCGAATTCTTTCATGGCGCAACTGCTGAAGAAAATCGGTCTGAGCGGCGTATATAAATCCAATGAAAAGGACACGCTGGTATTTTTCGACACCTTCTTGCTGCTCCGCTGCCTGGGTGAAGTCGTCGTCGGTTTTATCAAACAACCGGTCTACCTGCTTAAACCCGCCGTCTGGCGCCTGACGGGACAACTATTCCTGCATGCCTTGATCGGTAAACCTTATGTTATCGCGGCAAAACAGCTGGGCGATCCGATCTTTGCCGATCTGTACGCCTTCCTGGATACCTTCTCGCCGCGCGGCGAGCGCTACCCCAGCCTGCCCTGGACGCCGCAGAGCGCCTGGAGCAAAACGAATATGGCGCTGCTCGACACTATCCCGCTGTACACGTATCTGTTCGAACCGCACAAACTGGATCAGATCCCGACGGATCTGCGGCCACCGAGAAAATTCGGCAAGCTGGTAGAGAATGCCGTCAGCACCACGCTGCGCGTGGAATGTCTCGATATTCGCGAAGTCTCCGCCTATGTCGGATTGCACTTCCTGGTGGGGTATTTACGCGGCAATCTGGTCACGCTGCCGGGCGGTAACGGCAGCATCAGCGCCGGGCTGCTCGACTATCTTGAGGAGCAAAACAACGTCAGGCTGCAAAGCCGCGTACAGCTTCAAAGCATCACGCCCGGCGGCGACGAAACGGTGATCCGGTTCAGCGTCAATGGCGCGGCCAGCGAAATCAGAGCCAAACAAGTGATCTGGGCCGCCCCCAAAACGCATGTGCCCACCTGGTTGCCCACCCTGCCCAAAGAGCAATTGGCGGCGATCCGCCAGATCCGCCATGAAGATTACTACCTGGCGAACGTGCTGTTGAAAAAACCGATCCTCGAACGCTCGTTCGGCGGCTATCTGATCGAGCCGGAAAACACCCGCACACCTTACTATTGGAGCAAAGCCGGCACCTGCCTGGTCGCCAATTGGATGGACAATCACCTCAGCGCGGAAGCCGGGGTATTAACCCTGCTCAAACCAACCACTCGTCCAGAACGGCAAGGTCGCACCGCGCAAAACGAGTTCCCGGCGCTGCAGCAACAGACCTATGTCGAAATCGCCAAAGTGCTGGGCAACATGGGCATTGACGCCGACGTCATTGAAGACATTCAAATCTGGTTCTGGCCCGCGGGTCTGGTGACCTCGGTCGCCGGGCAACAGGCCCAGGGCGTGTTTCACCAGGCCAGCAGGCCGTTTGAGAATATTCACTTCGCCAATCAGGACAGCGTGGGCATCGGTAATATCGAAAGCGCGGTGTTAGCCGGACTGAACGCCGCCAAAGCGGTGAGAGAACGCCTCGCAATGCCCGTTACGTCTGCGGAGGTGATGTCATGA	MIVQRVFAVLYMLAGLAKAFPQLENVADILQQAAVANQGTWYAGATAWLAAQGTVVNALIGVALFASGAVLMFNPRWTPLIIYCQLLMMAGFVTILHRAQPQVMLLDAIFALAALYMLRQQHHRKPKPRTFPTRDFSTPTPAAGGPVTPALDGEYDVVIIGGGVSGLAAASELTDRRVLVLEKSASFGGNARYSTVNRLKFPIAGVCFQEPLPNSFMAQLLKKIGLSGVYKSNEKDTLVFFDTFLLLRCLGEVVVGFIKQPVYLLKPAVWRLTGQLFLHALIGKPYVIAAKQLGDPIFADLYAFLDTFSPRGERYPSLPWTPQSAWSKTNMALLDTIPLYTYLFEPHKLDQIPTDLRPPRKFGKLVENAVSTTLRVECLDIREVSAYVGLHFLVGYLRGNLVTLPGGNGSISAGLLDYLEEQNNVRLQSRVQLQSITPGGDETVIRFSVNGAASEIRAKQVIWAAPKTHVPTWLPTLPKEQLAAIRQIRHEDYYLANVLLKKPILERSFGGYLIEPENTRTPYYWSKAGTCLVANWMDNHLSAEAGVLTLLKPTTRPERQGRTAQNEFPALQQQTYVEIAKVLGNMGIDADVIEDIQIWFWPAGLVTSVAGQQAQGVFHQASRPFENIHFANQDSVGIGNIESAVLAGLNAAKAVRERLAMPVTSAEVMS	MFDVIVVGGGPTGLMLAGELRLHGVRVLVLEKETEPTRQSRAQGLHVRSIEVMAQRGLLERFLERGHTVAVGGFFAGLATSWPERLDTAHSYVLAVPQVITEQLLAEHATALGAEIRRGRALVGLRQDEDGVTVDLADGEQLRARYVVGCDGGRSTVRKLLGVAFPGEPSRVETLLGEMEMTASQEELTSVMTEVRKTQQRFGAMPLGDGVFRVVVPAEGVAEDRTASPTLDEFKQQLRAHAGTDFGVHSPRWLSRFGDATRQAERYRVDRVFLAGDAAHIHPPTGGQGLNLGIQDAFNLGWKLAAEVDGWAPEGLLDTYHAERHPVATEVLDNTRAQIQLMSTEPGPQAVRRLMAELVEFENVNRYLIEKITAISVRYDVGEGHELLGRRMRDLALKHGRLYERMHEGRGLLLDQTGRLSVAGWEDRVDHVVEVSEELDVPAVLLRPDGHVVWAGEDQQELLTRMPAWFGAATAG	140.76	gnl|BL_ORD_ID|4833|hsp_num:0	5820			3	105	rifampin; rifaximin; rifapentine
BGC0000259.1|Prodigiosin_6 # 4148 # 6814 # 1 # ID=1_6;partial=00;start_type=ATG;rbs_motif=AGG;rbs_spacer=7bp;gc_cont=0.616	BGC0000259.1|Prodigiosin_6 	4148	6814	+	Loose	1500	258.84	rphA	28.37	3000444	protein homolog model	n/a	n/a	rifamycin antibiotic	antibiotic inactivation	rifampin phosphotransferase	ATGAATCCTACCCTGGTGGTTGAACTTTCCGGCGATAAAACGCTGGAACCCCATCGTCTGGGCGGCAAAGCCCATTCGTTGAATCATTTGATTCACGCGGGCTTGCCGGTGCCGCCGGCGTTTTGCATCACCGCGCAGGCTTACCGGCAGTTTATCGAATTCGCCGTGCCGGGAGCGCTGCTCGACACGGGCGCACCGGGCAACGTGCGCGATATGATTTTGAGCGCCGCCATCCCCGCCCCGCTCGATCTGGCGATCCGTCACGCCTGCAAACAGTTGGGCGACGGCGCCTCGCTCGCCGTGCGCTCTTCGGCGCTGGAAGAAGACGGCCTGACCCACTCTTTCGCCGGGCAATACGACACTTACCTGCACGTGCGCGGGGATGACGAGGTGGTGCGCAAGGTGCAATCCTGCTGGGCGTCGCTCTGGGCGGAACGCGCCGCCCAGTATAGCCGGACATCGGCGGCGCAGAGCGATATCGCCGTCGTCTTGCAAATCATGGTGGATGCAGACGCCGCCGGCGTCATGTTTACCCAAGATCCGCTGACAGGCGATGCCAACCACATCGTCATCGACAGCTGCTGGGGGCTGGGGGAAGGCGTGGTCTCCGGACAAGTCACCACCGACAGCTTCATTTTGGATAAGGCGAGCGGCGAGATCCGCGAGCGGCAAATTCGTCACAAACCGCACTATTGCCAACGCGATCCGCAGGGACGGGTCACGCTGCTGCAAACGCCCGAAGCCAGGCGAGACGCCCCCAGCTTAACCCCGGAACAGCTGCAACAGCTTGCCAGGCTGGCCCGGCAAACGCGGATGATTTACGGCGCGGAACTGGATATCGAATGGGCGGTGAAAGACGATCGCGTGTGGCTCCTGCAGGCGCGGCCGATCACCACGCAGGCCAAACCGGTTCAGATGCTTTACGCCAACCCGTGGGAAAGCGATCCGACGATCAAGGAACGGGCCTTTTTCTCCCGAATGGACACCGGCGAGATCGTCACCGGCTTGATGACGCCGCTGGGGCTGTCGTTTTGCCAGTTCTACCAAAAGCATATTCATGGCCCGGCGATCAAAACCATGGGGCTGGCGGATATCGGCGATTGGCAGATTTATATGGGGTATTTGCAAGGCTACGTCTATCTGAATATCTCCGGATCGGCCTACATGCTCCGACAATGCCCGCCCACCCGCGACGAAATGAAGTTCACGACCCGGTACGCCACCGCCGATATCGATTTCAGCGGGTACAAAAACCCCTATGGCCCCGGCGTACAGGGATGGGCTTATCTCAAGAGCGCCTGGCATTGGCTGAAACAGCAGAGGCATAACCTGCGCAGCGCCGGCGCGACCGTCGATGCCATGATCGCCCTGCGCCAGCGCGAGACGCGCCGCTTTCTGGCGCTGGATCTGACGACCATGACACATCAGGAACTGGAGCGAGAACTCAGCCGCATCGACGGTTACTTCCTCGACAGCTGCGCCGCCTATATGCCCTTCTTCCTTCAGTCGTTCGCGCTCTACGATGCGCTGGCGCTGACCTGCGAACGTTATCTCAAAGGCCGCGGCAACGGATTGCAAAATCGCATCAAGGCGTCGATGAACAACCTGCGCACCATCGAAGTCACGCTGGGCATTCTCAGCCTGGTGGAGACGGTCAATCGTCAACCGGCGTTGAAGGCCCTGTTCGAGCGACACAGCGCACAGGAACTGGTCACCGTCCTGCCCACCGATCCCGAATCGCGCGCCTTCTGGCAAAGCGACTTCAGCGCCTTCCTGTTCGAGTTCGGCGCCCGTGGCCGCCAGGAGTTCGAATTGAGTCTTCCGCGCTGGAACGACGATCCCAGCTACCTGCTGCAAGTGATGAAAATGTATCTGCAACATCCGGTGGATCTGCACACGAAACTGCGGGAAACAGAGCGGCTGCGCCATGAAGACAGCGCGGCGCTGCTTAAAGCGATGCCCTGGTTTGGCCGGATGAAGCTGAAGTTCATCACCAAACTGTATGGCGTGATGGCCGAACGCCGCGAAGCGACCCGGCCAACCTTCGTCACCGAAACCTGGTTCTACCGCCGCATCATGTTGGAAGTGCTGCGGCGCCTGGAGGCGCAAGGCCTGGTCAAATCGGCCGATCTGCCCTATGTGGACTTCGAGCGCTTCCGCGCGTTTATGGCGGGGGAACAGTCGGCGCAGGAAGCGTTCGCCGCCGATCTGATCGAGCGCAATCGCCACCAGCATCTGCTGAACCTGCATGCGGAAGAGCCGCCGATGGCGATCGTCGGGGGGTATCAGCCCAGGATGAAAGCCCCCACGGCGGAAAACGCCGCCGGCATGCTGTCCGGCCTGGCGGCCAGCCCCGGCAAAGTGGTGGCGAAAGCGCGCGTCATCACCGATCTGCTGGCGCAGGCCGGCGAGCTGCAGCCCAACGAAATCCTGGTGGCGCGCTTTACCGACGCCAGCTGGACCCCGCTCTTCGCGCTGGCGGCGGGCATCGTCACCGATATCGGCTCTGCGCTGTCCCACAGCTGCATCGTCGCACGCGAATTCGGCATTCCCGCGGCGGTCAATCTCAAGAACGCCACCCAGTTGATCAACAGCGGCGACACCTTGATTCTCGACGGCGACAGCGGGACGGTCATTATTCAACGCGGAGAACGTGCCGATGGCTAG	MNPTLVVELSGDKTLEPHRLGGKAHSLNHLIHAGLPVPPAFCITAQAYRQFIEFAVPGALLDTGAPGNVRDMILSAAIPAPLDLAIRHACKQLGDGASLAVRSSALEEDGLTHSFAGQYDTYLHVRGDDEVVRKVQSCWASLWAERAAQYSRTSAAQSDIAVVLQIMVDADAAGVMFTQDPLTGDANHIVIDSCWGLGEGVVSGQVTTDSFILDKASGEIRERQIRHKPHYCQRDPQGRVTLLQTPEARRDAPSLTPEQLQQLARLARQTRMIYGAELDIEWAVKDDRVWLLQARPITTQAKPVQMLYANPWESDPTIKERAFFSRMDTGEIVTGLMTPLGLSFCQFYQKHIHGPAIKTMGLADIGDWQIYMGYLQGYVYLNISGSAYMLRQCPPTRDEMKFTTRYATADIDFSGYKNPYGPGVQGWAYLKSAWHWLKQQRHNLRSAGATVDAMIALRQRETRRFLALDLTTMTHQELERELSRIDGYFLDSCAAYMPFFLQSFALYDALALTCERYLKGRGNGLQNRIKASMNNLRTIEVTLGILSLVETVNRQPALKALFERHSAQELVTVLPTDPESRAFWQSDFSAFLFEFGARGRQEFELSLPRWNDDPSYLLQVMKMYLQHPVDLHTKLRETERLRHEDSAALLKAMPWFGRMKLKFITKLYGVMAERREATRPTFVTETWFYRRIMLEVLRRLEAQGLVKSADLPYVDFERFRAFMAGEQSAQEAFAADLIERNRHQHLLNLHAEEPPMAIVGGYQPRMKAPTAENAAGMLSGLAASPGKVVAKARVITDLLAQAGELQPNEILVARFTDASWTPLFALAAGIVTDIGSALSHSCIVAREFGIPAAVNLKNATQLINSGDTLILDGDSGTVIIQRGERADG	MSGRLVVDLQDVDAAGLAEVGGKGAHLGELSRIDGVRVPSGFCVTTHAFRRIMAEAPESGELLDRLSRVDEGDQEAVRSLAARLRQVVGATPLPDEVAAAVTGALARHGERSAYAVRSSATAEDLPTASFAGQQDTYLNVVGTEEILRHVSRCWASLFTERAVTYRGRQGVDHRTVHMGVVVQRMVVPRASGILFTADPVTGDRRTATVDAGFGLGEALVSGLVDPDVLTVRHGEVVARTIAAKRRALHAVQGGGTRETPIEERRQREPVLTDDQAVELVALGRRIEAHFGSPQDIEWCLDDDGFHIVQSRPITTLFPVPERDDDVFRVYLSVGHQQMMTDAMKPLGLSMWRLTALAPMYEAGGRLFVDATARLAVPGSRATLLDVVGRGDPLTRDALETVLENGEFEPTPAETDGGAPPAGDGAEPDEADPSIVTELIERSRRSLAELEREIGTKSGPALFAFLREAFEEHKRVVGDPLNIRAIMAGMEATWWLNDRLEEWLGEKNAADTLTLSAPDNVTSEMGLELLDVADVVRTHPEVVAFLEGVEDDGFLDELPKVPGGAEARDAFEAYLDRYGMRCVGEIDITXPPVRERPSALVPVVLDHVRAFGPGAAARRFEDGRRRALAKEREVLERLRDLPDGERRADAARRMIRQVRAFAGYREYPKYAIVSRSFVYRQALLREADELVRAGVLADREDVHYLTFDEFEEAVRVRRVDERLVRRRKDAFRSYQALTPPRVLTSEGVALSGAYRRDDVPEGALAGLAVSAGTVEGRARVVLDMAEADLEAGDILVTRFTDPSWSPLFVGIAGLVTEVGGLMTHGAVIAREYGLAAVVGVERATRLIRDGQRIRVHGTEGYIELLS	102.66	gnl|BL_ORD_ID|890|hsp_num:0	910			0	2583	rifampin; rifaximin; rifabutin; rifapentine
BGC0000259.1|Prodigiosin_7 # 6985 # 9591 # 1 # ID=1_7;partial=00;start_type=ATG;rbs_motif=AAGGA;rbs_spacer=7bp;gc_cont=0.602	BGC0000259.1|Prodigiosin_7 	6985	9591	+	Loose	275	31.187	AAC(6')-34	30.77	3003989	protein homolog model	n/a	n/a	aminoglycoside antibiotic	antibiotic inactivation	AAC(6')	ATGACGACCCTGACAGGACAAGCAAGACTCACCAACTCCGCCGCCTACGAGCAAGTGTGGCAAGCGGAGCGCCAGGCCTGCCGCACCGACGCGGATCCCGACACCCTGACGGTCGGCGTGGTGGTGGTGACGCGCAACCCGGCGTTTTTCCAAACCGGGCTTAGCGTACTGAACGATATCCGCGATTATGTTTTCAACCGCGTGCATATCCAGTCCGAGATGCCGCTGAAACTGTTGGATCTGGCGGCGGACTCGCTTTATCTGGCCGCGCGCGAAAAGGCGCTGCACTTTCTCAAAGGCCAAAACAAGGCTATCAACGTTCGCATCATCCAATGCGCCAGCCTGGCCGAGGCCACCGGCAAGATCATCTATACGCATGCGCTGGAACAGCGTCCCGAATTTCATTTGGGCATGCTGTTCTACGATCAGACCACGCCGGCCGGCGTCGATGACAGCATCGAACAGATCGATCGCGATCTGGACGCCTTTTACAGCGCCTTGCAGCGCAGCGGCATTCCCGCGTTTTACACCACCTTCTCCACCGTTGCGTTCATTCGCCAGCTGCGATCGCCCTTCCGCTACCTGCCGCAGCAATACCGCGAAATCGTGCGCAGCGAAGATCCGGCGATCTTCCAAACCGAGCTGTTGTGCCTGTGGATGGACTTCTTCGAGATGAACTACACCAACCGCCGGGTCAAGCCGATCGGCGCGCTGGCGCTGCACAACACGCTGGGTGAGCAGCTGATTCAATTTTTCGAGCGTACCGCCGCCGAACGCTGGCTGGTGTCCTATTACACCGGGTCGATCATCTCCAATCTGATCGGCTATCTGGATCGGCATGCGGAGGCGCGCGGCGCGCTGATCCTGCGCGGCCCTAACGAACACGCCATCGCCTGCGGCGCCATGGCCAACTGGCAGCTGTATCGCATGCCGTTCCTCGGCGTAGTGACCTCCGGGATGATGGATGAATTCAAGGGCACGCTGGCCAACCTCAAGGAAACCGCCGCCCAGGGCATCATCGTCGCGGCGGAAAACCGCGGCAATCAATGGTACAGCTTCCAGGGAACGCTGACGCCGACGGAGGACATGCGCGAAGTGCTTATCGCCCGCCGCATCCCGTTCGTTTATATCGATGACGTCGAAATGATCGGCGCCGGTTTGACGGAAGCCTTCCGCCTTTATCATCAAGGCCAGGGGCCAGTGGTGATTCTGGCGACGCAAAACGTGCTGGAGTCGACCCTGTCGCTGGAGGGCGCCGTCTGCGATCCCTCGCCGATCCCGGTTCTGTCGGCGGACGATCCGCTGCCGATGAGCGAAAGCCTGGCACAGGCGATAGCGCTGATCAACCGCGGGCCGGAACGGTTGGTGTGGCAGTTGGGCCCGGTCAGCGACGACGAATACGCCCTGATCCATGACATCGCCGACGCCGCCGGCATCGCCCTGGTGGACTCGTTGGCCCATCCCGGCTCGGCGCCGAAATATTATCAGGGCCGGCGCAATCCCCACTACCTGGGCACCCTGGCGATTTACGGCTATAGCCCGCGCGTCTACAACTTCCTGCACACCAATGACAAGCTCAACGCCATGAGCGAGCAGAGCCTGTTTATGATCAAAAGCCGCGTCGCTCAGATCACCACCCCCTTCTCCGACGGCAGGCTGGAGCGCAAGGTTCATCTGGTGCAGCTCACGCACGATGACCGCCATCTGTCGGCCTATGCCGATCTGCACCTGCACATGAACTGTCTGGCGTTCCTGCGCACGGTGAAAGCGCATCTCGACGTCGATCCGGCATTGCGGGAAAGACGCCGCGCGTTGATCGCCGCCTATCTCGATTCGCCTTCCGACGTGGTCAGCCAGCTTCCCAGTCTGCCCATGTCGGCCAACTACTTCTTCTGCCAGTTGAACCGAGTGATTGAAGAGTTGATCGAAACGGAGGGCTTCGATTTTACCGGCGTATATGACGTCGGCCGGTGCGGCATCTCCGCCGCGCGCAACGTCGCCAAAACGCGCCGCGGCTTTTCCGGCTGGTATGGCCGCGCCCTGATGGGCGACGCTCTGCTGGCCACCGGCTACCTGGCTTACACCAGCCCAAGCCACGTGATGGCGTTTATCGGCGACGGCGCTAAAGGGATCGTACCGGACATCCTGCCGGCTTTTATCGACAACATTCTCACCCATCCGCAGTTGCTGAATAAAAGCATCACCGTCTTCTATTTATGCAACGGCGGTCTGTCCGTCATCAATACCTATCAGGAACGCATTCTGTTCAATCGCACCTCGCGGCAAATGCGGTTGGTGAACGTCGAACAGCCGGACGTCGAACAAACGGTCAATAACTTCCATATCCAGAGCAAAACGCTTACGCATTTCGACGAAGACGTCATTCGCCAGGCGCTGACCACCTCGCACCGACTCAATCTGTTCTCCGTGGTGCTGGGGCACAACAATGAAGGCGACGGTATCTCGCCTGGCCACCGCCAAAGGCTGGCAGCGCTGATCCGAGCAGACCACGACGCCCTGCAGGAGCGCAAAGCCTGGGCAGCCCAACAGCCCGAATCGACCAGCACCGCCTTCGACCAAGATCCTACACAGGAAGCCACCTCATGA	MTTLTGQARLTNSAAYEQVWQAERQACRTDADPDTLTVGVVVVTRNPAFFQTGLSVLNDIRDYVFNRVHIQSEMPLKLLDLAADSLYLAAREKALHFLKGQNKAINVRIIQCASLAEATGKIIYTHALEQRPEFHLGMLFYDQTTPAGVDDSIEQIDRDLDAFYSALQRSGIPAFYTTFSTVAFIRQLRSPFRYLPQQYREIVRSEDPAIFQTELLCLWMDFFEMNYTNRRVKPIGALALHNTLGEQLIQFFERTAAERWLVSYYTGSIISNLIGYLDRHAEARGALILRGPNEHAIACGAMANWQLYRMPFLGVVTSGMMDEFKGTLANLKETAAQGIIVAAENRGNQWYSFQGTLTPTEDMREVLIARRIPFVYIDDVEMIGAGLTEAFRLYHQGQGPVVILATQNVLESTLSLEGAVCDPSPIPVLSADDPLPMSESLAQAIALINRGPERLVWQLGPVSDDEYALIHDIADAAGIALVDSLAHPGSAPKYYQGRRNPHYLGTLAIYGYSPRVYNFLHTNDKLNAMSEQSLFMIKSRVAQITTPFSDGRLERKVHLVQLTHDDRHLSAYADLHLHMNCLAFLRTVKAHLDVDPALRERRRALIAAYLDSPSDVVSQLPSLPMSANYFFCQLNRVIEELIETEGFDFTGVYDVGRCGISAARNVAKTRRGFSGWYGRALMGDALLATGYLAYTSPSHVMAFIGDGAKGIVPDILPAFIDNILTHPQLLNKSITVFYLCNGGLSVINTYQERILFNRTSRQMRLVNVEQPDVEQTVNNFHIQSKTLTHFDEDVIRQALTTSHRLNLFSVVLGHNNEGDGISPGHRQRLAALIRADHDALQERKAWAAQQPESTSTAFDQDPTQEATS	MRIGDLIREDGGIAMLVYEAGPITVRELEEKDEISLASWLSNPDVLQYYEGRDNPHDVERVREHFYVDDDETRCIIKYEGKPIGYIQFYLLDEETLGEYGYNESDADCRTFATDQFIGEPDYWNRGIGTKLMTSMVEYLVFQRQADRIVMDPQAWNERAIACYEKCGFRKVRLLEKHEQHEGELRDCWIMEYRAERK	440.61	gnl|BL_ORD_ID|2233|hsp_num:0	2525			33	168	kanamycin A
BGC0000259.1|Prodigiosin_9 # 12160 # 13176 # 1 # ID=1_9;partial=00;start_type=ATG;rbs_motif=AGG;rbs_spacer=9bp;gc_cont=0.615	BGC0000259.1|Prodigiosin_9 	12160	13176	+	Loose	400	30.0314	Erm(42)	21.78	3003106	protein homolog model	n/a	n/a	macrolide antibiotic; lincosamide antibiotic; streptogramin antibiotic	antibiotic target alteration	Erm 23S ribosomal RNA methyltransferase	ATGCCTTTAACCAAGCAAGATGCCGTCAATCAGATGATGGGCTTTTTCCAGGCCAAGGCGCTGACCGCCGCGCTTGCGCTGAAGCTGTTCGATCAGCTGCGCGATCGGGACGCCGACGCGGCGCACATCGCCGCGCGGCTTGACTGCCCGGCGCGTTCCACCGAGCAGTTGCTCATCGCGCTGCGGGCCATGGGGTATCTCGACCAACGAGACGGCCTTTATCATTTGCCCGCCGCCCACCGGGCTTTTCTGTTGAGCGACGAACCCCAGTGGCTGGGATGGCTGGGCCGCCACATCGATACCTTCCTGTATCCGCTATGGGGCGAGCTGAAAACGGCGGTGCGAAACGATGCCCACCAGCGCCGCACGGTATTCGGCGATGACCGCAGTTGGTTCGACATCCTGTACCAAAATCCGGACGACGTGGCGGACTTCCAGGAATTTCTCGGTAAATTCGCCGCGCCCTTTATCGCCGGCTTTGTTCGCGATTACGACTTCTCGCAACACCGTGCGTTTTTGGACATCGGCAGCGGGATCGGCAGCCTGCCGATGGCGATCGCCGACGCTTATCCGGGGATCGCACTCGCGATCTGCGAACTGCCGCAGGCCTCGGCGTTCTTGCGCGACAAGCTGACGCTGCAAGGCTATGGCGAACGCATTGACGTCGTGGAGGGCGATGTCATCAGCGGCGATCTGCCGATCGGCGGCTATGACCTGATCCACCTGGGATGGATGCTGCACGACTACGCCCCGGAAACCCAACTGACCATCCTGCGCAACATCTATCGGGCGATGCCGGCCGGCGGCCGCTTCATCGCTTCCGAAACGCCGCTGAACGAAGACAAATCAGGGCCGGAATTTACCGCCCTGCTGTCGCTGAACATGCTGGTCTCCACCGACGGCGGCATAGAGAGCAGCGCGCAGGAATACCTGGACAGATTCCGTCTGGCGGGATTCAGCAACGCGCGCATCATGAAAATAGCCGGCCCACGCACCCTGATCGTCGGCGAAAAATAA	MPLTKQDAVNQMMGFFQAKALTAALALKLFDQLRDRDADAAHIAARLDCPARSTEQLLIALRAMGYLDQRDGLYHLPAAHRAFLLSDEPQWLGWLGRHIDTFLYPLWGELKTAVRNDAHQRRTVFGDDRSWFDILYQNPDDVADFQEFLGKFAAPFIAGFVRDYDFSQHRAFLDIGSGIGSLPMAIADAYPGIALAICELPQASAFLRDKLTLQGYGERIDVVEGDVISGDLPIGGYDLIHLGWMLHDYAPETQLTILRNIYRAMPAGGRFIASETPLNEDKSGPEFTALLSLNMLVSTDGGIESSAQEYLDRFRLAGFSNARIMKIAGPRTLIVGEK	MNKNTKIKNKNFNIKDSQNFLHNTKLVEDLLFKSNITKEDFVVEIGPGKGIITKALSKICKAVNAIEFDSVLADKLSHEFKSSNVSIIEADFLKYNLPDHNYKVFSNIPFNITASILNKLLDSENPPLDTFLIMQYEPFLKYAGAPSYKESYKSLLYKPFFKTNILHSFSKFDFKPAPNANIILGQFSYKDFTDINLEDRHAWKDFLAFVFLEKGVTFKEKTKRIFSYKQQKIILKESRINDDSNISNWSYEFWLKMFKLYNSNMVSKDKKVLVNNSYKRMLEHESSLEKIHRNRKQNNRK	112.29	gnl|BL_ORD_ID|643|hsp_num:0	697			39	312	erythromycin; clindamycin
BGC0000259.1|Prodigiosin_10 # 13200 # 13463 # 1 # ID=1_10;partial=00;start_type=ATG;rbs_motif=GGA;rbs_spacer=7bp;gc_cont=0.557	BGC0000259.1|Prodigiosin_10 	13200	13463	+	Loose	500	22.3274	HERA-1	52.63	3004448	protein homolog model	n/a	n/a	penam	antibiotic inactivation	HERA beta-lactamase	ATGTTAGAAAGCAAATTGATCCAGCATATCGCCACCCAGTATCTGGATGGCGATCACGACGGCCTGAACGCTCAAACCCCGTTGTTTGAACTGAACGTCGTCGATTCCGCCTCCATTTTCGATCTGGTGGATTTTCTGCGTCAGGAGTCTCATGTCGCCATCGGCATGCATGAGATCCATCCGGCGAACTTCGCCTCGGTGCAGGCGATGGTTGCGCTGGTGCAACGGTTGCAAGCGCAAGTCGCCGCAGGGGGTGTCGCATGA	MLESKLIQHIATQYLDGDHDGLNAQTPLFELNVVDSASIFDLVDFLRQESHVAIGMHEIHPANFASVQAMVALVQRLQAQVAAGGVA	MKKITPLFVIAFLTLIALLAPAQASVTPDMTDFLRQQEQRLHARIGMAVVNAQGETVFGYRQDERFPLTSTFKTLACAALLERLQKNGGSLDEQVTIPPDALLDYAPVTKNYLAPATISLRMLCAAAVSYSDNTAGNRILTYLGGPDAVTQFMRGIGDHVTRLDRTEPTLNEATPGDARDTSSPQKMAAGLQKILTSPPLISANRATLAQWMRDDKVGDALLRAALPKGWAIADKTGAGGYGSRAIIAAVYPPERPPFYVAIFITQTEASMKMANETIAEIGKQLFAGQP	30.00	gnl|BL_ORD_ID|2497|hsp_num:0	2888			84	141	
BGC0000259.1|Prodigiosin_11 # 13460 # 15406 # 1 # ID=1_11;partial=00;start_type=ATG;rbs_motif=AGG;rbs_spacer=9bp;gc_cont=0.624	BGC0000259.1|Prodigiosin_11 	13460	15406	+	Loose	550	27.335	IMI-9	30.59	3003143	protein homolog model	n/a	n/a	carbapenem	antibiotic inactivation	IMI beta-lactamase	ATGAGCGTTCACGCCGTCGATAGCGCCGCAAACGCGCATGAAGCCGTCCGGCAGTCGGTGCTGCACACCTTCGCCCGGCTGACCGAGTATGAACCGTCGGCACTGGCCCTGACCAGCCATCTGGAAAACGATTTGGGCGTCGACTCCATCGCGCTGGCGGAAATTGCCATGGTGCTGAACCGTCAGTTCCAATTAAATACGCCGCTGGCGATCCAGGAGATCAAAACCATTCAGGATGCGCTCGACGGTATTTTGCAGCGCGGTTTCACGCTGCCGACGCCGAACGCCGCCGCGCAACCTGCCCCCCAGACGCCTCAGGCCTGGTTGAGCGCTCTCGTTCGCCAGGTGTTCGCCACCCACAGCGGATATGAAGTGCGTGATCTGTCCCCCGACGCCGCCATCGAAGGCGACCTGGGCATCGACTCCGTAGCGGTGGTGATGGCGCGCAACGAGTTGCTCAAAACGCTGGGCCTGGACGATAACGCAGCGCTGGCGGAGTGCCGCACGCTGGCTGAGCTGGAGCACAACCTGGCGGCGCGGCTGGTTCAGGAACAGGGCGAAGCGTGGTTCAGCCGCTTTGGCCAGCACACCACCGCGTCCGCCGCGCCGCAGCCCACCAAGGCGCCCGCATCGCCGGACGCGCGCGATGAGCTCGGCGATCCGCGCACCATGCGGGACTTCGTCGGCATCGAGCACCCGGATTTGTTCCATAAAACGCGTGAATTCGGCGCTTTTTATCGCGATAAAAAACAGCGTCAGCTTTACTGGTACGGCATGCCGCTTGAAACGCCGTGCAAAAACCGCGCGGTCATGTTCGACGAGGTCACCGGCAAAAGCCGCGAATTTCTGATGTTCGGCTCCAACAGCTATCTGGGATTGTCGAACCATCCGGAAGTGATCCACGCCATCCAGGACGCCGCTGGCCTGTACGGCGCCACCAACACCGGGTGCCGCATCATCGCCGGCAGCAACGTGCTGCATCTGGAATTGGAGCGCAAACTGGCCAAGCTCAAAGGGCGCGAAGACTGCATCGTCTATCCGTCCGGCTACTCGGCCAACCTGGGATGCATCTCGGCTCTGACCAGCCGACACGACCTGGTGTTCACCGACGCCATCAACCACATGAGCATCCAGGACGGCTGCAAGTTGGCGGGCGCGCAGCGGAAAATTTATGACCACTCTTTGACCAGCCTTGAGAAATCGCTGGCCAAATACGCCGATCACCCCGGCGGCAAGCTGATCGTCACCGATGGCGTTTTCAGCATGCACGGCGATATCGTCGATCTGCCGCGCCTGATGAAGCTGGCCGAACGCTACGGCGCACGCGTATTGGTCGACGACGCGCACGCGACCGGCGTCTTGGGCAAAACCGGCTCGGGCACGGCGGAACACTTCAATATGAAAGGCCAGGTGGATCTCGAACTGGGCACCATGAGCAAGGCGCTGTCGGGGTTAGGCGGCTTCGTTTGCGCCGATGGTGAAGTGGTCGAATACCTGCGTTTCTACTCCAACTCCTATGTTTTCGCCGCCACCATCCCCGCCGCAGTCGCCGCCGGCGTGATCGCCTCCATCGACGTGATGCTGCGTGAACCCGAGCGACTGACCAAGCTGTGGGACAACATCTACTACTTCCGCACGCTGCTGCTTAACGCCGGTTTTGACCTTGAGCATTCCGACTCGGCCATCATTCCGGTGGTGGTGGGCGACGACGCCAAAACGCTGCTGTTCGGCCGCGCCGTCCGGGCGCGCGGGCTATTCTGCCAGACCGTGGTCTTCCCGGGCGTCAGCGTGGGTGACGCCCGCTTACGCATCAGCGTGACCAGTGAACACACGCGTGAAGATCTGGATGAAGCCAACGCCATTTTGGTGGCGGCGGCGCTGGAGACCGGCGTGCCGGTCAACGGCGATGTTCGACGGGAAGAGCGCGCACGCGCCACCGAGGTCTGA	MSVHAVDSAANAHEAVRQSVLHTFARLTEYEPSALALTSHLENDLGVDSIALAEIAMVLNRQFQLNTPLAIQEIKTIQDALDGILQRGFTLPTPNAAAQPAPQTPQAWLSALVRQVFATHSGYEVRDLSPDAAIEGDLGIDSVAVVMARNELLKTLGLDDNAALAECRTLAELEHNLAARLVQEQGEAWFSRFGQHTTASAAPQPTKAPASPDARDELGDPRTMRDFVGIEHPDLFHKTREFGAFYRDKKQRQLYWYGMPLETPCKNRAVMFDEVTGKSREFLMFGSNSYLGLSNHPEVIHAIQDAAGLYGATNTGCRIIAGSNVLHLELERKLAKLKGREDCIVYPSGYSANLGCISALTSRHDLVFTDAINHMSIQDGCKLAGAQRKIYDHSLTSLEKSLAKYADHPGGKLIVTDGVFSMHGDIVDLPRLMKLAERYGARVLVDDAHATGVLGKTGSGTAEHFNMKGQVDLELGTMSKALSGLGGFVCADGEVVEYLRFYSNSYVFAATIPAAVAAGVIASIDVMLREPERLTKLWDNIYYFRTLLLNAGFDLEHSDSAIIPVVVGDDAKTLLFGRAVRARGLFCQTVVFPGVSVGDARLRISVTSEHTREDLDEANAILVAAALETGVPVNGDVRREERARATEV	MSLNVKPSRIAILFSSCLVSISFFSQANTKGIDEIKNLETDFNGRIGVYALDTGSGKSFSYKANERFPLCSSFKGFLAAAVLKGSQDNQLNLNQIVNYNTRSLEFHSPITTKYKDNGMSLGDMAAAALQYSDNGATNIILERYIGGPEGMTKFMRSIGDKDFRLDRWELDLNTAIPGDERDTSTPAAVAKSVKTLALGNILNEREKETYQTWLKGNTTGAARIRASVPSDWVVGDKTGSCGAYGTANDYAVVWPKNRAPLIISVYTTKNEKEAKHDDKVIAEASRIAIDNLK	221.92	gnl|BL_ORD_ID|3609|hsp_num:0	4678			438	690	
BGC0000259.1|Prodigiosin_12 # 15411 # 16883 # 1 # ID=1_12;partial=00;start_type=ATG;rbs_motif=AGG;rbs_spacer=9bp;gc_cont=0.637	BGC0000259.1|Prodigiosin_12 	15411	16883	+	Loose	1000	145.206	almE	26.73	3007433	protein homolog model	n/a	n/a	peptide antibiotic	antibiotic target alteration	polymyxin resistance operon; alm glycyltransferase	ATGGCAACCTTCATTTCACCGATACTGGAGGCCCTGTTCCGGCACGCCCGCCAAGCGCCGGAAAGCACCGCTCTGCTGTGCGGCGATCGGCGCTGGAGCTATCGTCGCCTGGCCGATCGCGCCTGCATGATGGCGGCGGCGCTGCGACATGCCGGGTTGAAGCAGCAGGCCGTGCTGCTCAACCTGCAGAAAGGGCCCGACGCCGTCGCCGCCATGTACGCGTGTTGGCTGAGCGGCAACCACTATGTCCCTATCGATTTCAGCCAACCGACGGCGCGCATCGAACGCATTATCGCCGCCGCCTCACCCGCGCTGATCGTCGATGAGGGCTGGTTGAGCGCGCTCGATGACCGCACCGATCTCGATGGCGCCTGGCCGGAAGCGATCGCCGCGTTCGGCTCTCCCCTCGCCGCCATTCTCTATACTTCAGGCTCCACAGGCACCCCGAAAGGGGTGCAAATCACCCATGACATGCTGACGTTTTTCATCGGCTGGGCCGTCAGCGATACACAACTGACGGCGCGCGACGTACTGGCCAACCATGCCAGTTTCGCCTTTGATCTGAGCACCTTCGATCTGTTCGCCGGCGTTTGTGCCGGCGCCGCGACCTGGATCGTGCGCGAAGATGAACAGAAAGATTGCCAGGCTCTCGTTCGCGGATTGCAAACGCACGGCGTCACCCTGTGGTATAGCGTGCCTTCGATTTTAGCCATGCTGGAAAAGAGCGCGTTGCTGGCGCCGTCGACGGTGAAAACGCTGCGCCAGGTCACGTTCGCCGGAGAGCCTTATCCGGCCGCCGCGCTGAGGCGCCTGGTTGCGCATCTGCCGGCCCGCTGCCGCGTCAGCAACTGGTATGGCCCGACGGAAACCAATGTCTGCACCGCCTACGCGCTGGATCGAACGCAGTTGGCGACGCTGGAGCAGATCCCCATCGGCCATCCGCTGCCCGGCTTGACGGCGCAGTTGGTCGATGAGCAGGGGCGTTGCAGACGATTGACGTCGCCGGGCCGACGCGGAGAATTGCTGATCGGCGGGCCGTGCGTTACCCCCGGCTACAGCAACGTCGCCTCATCGCGGCAAGCGCAATGGCATCCGCGCCAATGCCACGCGACCGGCGACTGGGTGGAGACGACGGCGAATGGGCTGGTCTATCGCGGCCGGCTGGACGACATGGTGAAAATCAACGGCTACCGGGTGGAATTGGGGGAGATAGAATCGATCCTTCATCACCATCCCTCGGTCTGCCAGGCCGCACTGTATGTCGAGCTTGGCGAGCTGAAGCAAAAACTGATCGCCGTGATCACCCTTCATCCCGGCGCGCTCCGCCCCAACCTGCTGGAGCTCAAGCAGTTCCTGCAGCCCAGGCTGCCCGCCTATATGCTCCCCAGCCAACTGGTGGTCGCCGACAGCCTGCCCACCAACGCGAACGGCAAGGTGGACAGAGGACGTTTGTCCGAGGTGAATGCGCGATGA	MATFISPILEALFRHARQAPESTALLCGDRRWSYRRLADRACMMAAALRHAGLKQQAVLLNLQKGPDAVAAMYACWLSGNHYVPIDFSQPTARIERIIAAASPALIVDEGWLSALDDRTDLDGAWPEAIAAFGSPLAAILYTSGSTGTPKGVQITHDMLTFFIGWAVSDTQLTARDVLANHASFAFDLSTFDLFAGVCAGAATWIVREDEQKDCQALVRGLQTHGVTLWYSVPSILAMLEKSALLAPSTVKTLRQVTFAGEPYPAAALRRLVAHLPARCRVSNWYGPTETNVCTAYALDRTQLATLEQIPIGHPLPGLTAQLVDEQGRCRRLTSPGRRGELLIGGPCVTPGYSNVASSRQAQWHPRQCHATGDWVETTANGLVYRGRLDDMVKINGYRVELGEIESILHHHPSVCQAALYVELGELKQKLIAVITLHPGALRPNLLELKQFLQPRLPAYMLPSQLVVADSLPTNANGKVDRGRLSEVNAR	MPYNSATDLLQREGYGVVHNQFINKMAMCCETRHSILAAIQANRHAPALWVKQKTYTYQEMTDMALSLSDYWHLQGVQRVAILSVRDLAAYSAIWASYLGGMTYIPLNARATTEQIQETLIATQCDSIMVDAQQLSRLSSLLDTCIDRLHIYALPDVDMEPLRQQYPQHTFHTVQITEQDVELLVAKYHLDNEHEYAYIMQTSGSTGKPKRIAVSYSNLHCYISQIDKLFPLNAQDRVGQYSDLTFDLSVHDIFYSLISGACLYVVPELAKLSPAEFIRHHQLTVWLSVPTVIELALQRQTLTPHSLPSLRLSFFCGQALLHDLAEQWQQATQQPVINLYGPTECTIAITYHRFVAHSGMASVPIGRAFEEECLAIINEQGELMRFESAPEGYRGELLLSGKQLVNGYLNDPLNTQSAFFQHEGRIWYRSGDIVTKSNGVLIHLGRRDHQVKIAGQRVELEEIETVVRRVTQAHSVAIVPWPLSESGYASGTVAFVDTHTQWQPDLWLSQCKQQLNPTFVPKRWYAIEQLPRNANGKTDIKALQQQLASQTYETSH	88.13	gnl|BL_ORD_ID|4935|hsp_num:0	5928			129	1635	colistin A; colistin B
BGC0000259.1|Prodigiosin_13 # 16880 # 19168 # 1 # ID=1_13;partial=00;start_type=ATG;rbs_motif=AGG;rbs_spacer=10bp;gc_cont=0.654	BGC0000259.1|Prodigiosin_13 	16880	19168	+	Loose	750	82.4185	Mycobacterium tuberculosis kasA mutant conferring resistance to isoniazid	28.32	3003463	protein variant model	G269S	n/a	isoniazid-like antibiotic	antibiotic target alteration	antibiotic resistant kasA	ATGAACCAGGAAATTCATGCCGCGCCGCTGGCGCTGGTCGGCATCGGCTGCGCACTGCCCGGCATCGATCGTATCGATCTGTCCAACGGCGCCGCCTGGTCGGCGCTGTTCGACGCCCCGCCGCCGATGCCGTGGAGCGATGCGGCCGCGCCGATCCGCGGCCGCCAGATCGACGACGCCGCGTTTGATTTCAAAAAATTCGCCATCCCGCCGCTGTTTCGACTGGCGGTCAGCCGCGAGACCCGCCTGGCGCTGCAGGCCGCCTCCGCCGCCATGCAGCATCTGACGTTATCCGACGCGTTGCGCGACCGCTGCGATCAATTTTGCGCCACCCATTTGGGCAGTGATGCCGCCTATCGCAACGCCACCAAAATCGGCGCGCTGCGCAGGCTGGCCGAACGGCTTGACGCTCAGGGGCTCTCACCGGCGGCGGTCATGCGCCGGATTGACGATTACAAACAGCCGCTGGCCCAGGCGTTCGGCAGTTCATCCCACGATCGCGTGGGGGAAATGGCCTCCAGCATTCCCGCGCGCATCGCCCATTTCGCCCGCACGCGCGGTAAATGCCAAACCCTCGACGGCGCCGATCTGGGCGGCCTGCGCTTGCTGCAGCTGGCACAAGACTGTTTTCGCCATGCCGACAGCCGCATGGCGGTGCTGACCGCCGTACAATGCTTCCACCATCAACCTCAGGCGGACATGCTGTTGGCGCAGGGCGTTTCCTCTTCGGCCTGTTGGCTGGAGGGCGCGATCAGCCTGGTCGTTTGCCCGCTGGACGTCGCTCAGGAACAGGGATGGCCAGCGATCGCGCAATTGTCGACCCTGATCGCCGAACGGCAGGATGCCGCGCCGAGCGCCGGCTATTTTGCCGGCGCCAATCAGGTTTTCTGCCATCTCCTCGACATGCTGTTGCAACGGCAACAGGCGTGCGCCGGCCACTCGTTCACCGGCTACCGCTGGCGGATCGACGCGGCGTCCCCCCCCTCATTAAAACCGACGGCTTCGCCACGCATCAGCATCATCGACTATCAGCCCATCACCGCGCAGGGGCTGGATAAAGCGCGTTTCTGGCAGGCCTTGCGCAACGGGGAGGACGCCCTGCGCGATCACAGCCCCGAGCAGCTGCACCCCGGCGCCTTCGTGCGCCCCACGCCGCAAAAGCTCAGCGCCTACACCGCTCACGCCATGTGCTTCCCAACGCACGATCCGGTGCAGCTTGAGCTGACGCGGCCTATGATGCCGGCCAAAAAACAGCGCCTCGACGTCACACAACTGCACGCCCTCAACGGCTGCGCGGCGTGGCCCGACAGCCTGCGACGCTTTGAACGCATCGCCATTATCGTCGCCAGCAACCTGTCTTTAAGCGCCGATCGACAACAGGCCATGCGCGCCCTGTGGCCGGCGTTGCCTCCCGCCGGCGTCTCCCTTTCGCCACCGCCCCAACCCGCGATCAACCGCTGGAGCTGGCATGGCGCCTGCGGCCTCGGCACCGCGCAGCTGTTGGCGCAACAGCTCGGCGTCGAGGCGGACTGCTACGCGGTCGAGGCGGCCTGCGCCAGTTCGCTGGCCGCCTTGCACAATGCGGTCAGGGCGTTACAGGCCGGCCGCTACGATGCGGTGCTCGTCGGCGGCATAGAAACGGCGACGCTCGAACGCGATATGGTGCTGTGCAGCGCGCAGATGATGCTTTCCGCTTCGCGTATGCGACCTTTCGCCCGACAAGCCGACGGTTTTACTCCCGGCGACGGTGGCGGCTTCTTCATTCTGACCGGCCAGGCGACATCGCGGGCCATCGCCACCATCGAAGCGATATCGGGATCTTGCGACAGCTATTCCATGACCGCGCCCGATCCCGAGGGCCAGGCGTTGGCAATCGAAAAAACCCAGAGCCTGAGCGCCGTCGAAGCGCGCCAGATACAGTATCTCGAAGCGCACGGCACCGGCACCGAACTGGGCGATCGGGCAGAAGTCGCGTCATTGCATCAGGGGTATCGCCGCGCCGCGCGCGCCCCTTTGTACATCGGTTCGGTGAAGTACAACTTCGGCCACTGTTTCGCCGGCGCCGGCGCGCTCAGCCTGTGCAAAGTGCTGAGCGCTTTCGAACACGGTCAAATCCCGCCCACGCCGGTGGCGACATTGAATGCCGAACTGCCGCTGGCGGCGATCCCGGCCGAAATCCCGCAAGTCGCGCTCGACTGGCCACACGGTGAAGGCGGACGTCGGGCGGCGATCAACGGCTTTGGCACCGGTGGCATCAATTACCATTTGCTTATCCATCAACCCGTTTAA	MNQEIHAAPLALVGIGCALPGIDRIDLSNGAAWSALFDAPPPMPWSDAAAPIRGRQIDDAAFDFKKFAIPPLFRLAVSRETRLALQAASAAMQHLTLSDALRDRCDQFCATHLGSDAAYRNATKIGALRRLAERLDAQGLSPAAVMRRIDDYKQPLAQAFGSSSHDRVGEMASSIPARIAHFARTRGKCQTLDGADLGGLRLLQLAQDCFRHADSRMAVLTAVQCFHHQPQADMLLAQGVSSSACWLEGAISLVVCPLDVAQEQGWPAIAQLSTLIAERQDAAPSAGYFAGANQVFCHLLDMLLQRQQACAGHSFTGYRWRIDAASPPSLKPTASPRISIIDYQPITAQGLDKARFWQALRNGEDALRDHSPEQLHPGAFVRPTPQKLSAYTAHAMCFPTHDPVQLELTRPMMPAKKQRLDVTQLHALNGCAAWPDSLRRFERIAIIVASNLSLSADRQQAMRALWPALPPAGVSLSPPPQPAINRWSWHGACGLGTAQLLAQQLGVEADCYAVEAACASSLAALHNAVRALQAGRYDAVLVGGIETATLERDMVLCSAQMMLSASRMRPFARQADGFTPGDGGGFFILTGQATSRAIATIEAISGSCDSYSMTAPDPEGQALAIEKTQSLSAVEARQIQYLEAHGTGTELGDRAEVASLHQGYRRAARAPLYIGSVKYNFGHCFAGAGALSLCKVLSAFEHGQIPPTPVATLNAELPLAAIPAEIPQVALDWPHGEGGRRAAINGFGTGGINYHLLIHQPV	MSQPSTANGGFPSVVVTAVTATTSISPDIESTWKGLLAGESGIHALEDEFVTKWDLAVKIGGHLKDPVDSHMGRLDMRRMSYVQRMGKLLGGQLWESAGSPEVDPDRFAVVVGTGLGGAERIVESYDLMNAGGPRKVSPLAVQMIMPNGAAAVIGLQLGARAGVMTPVSACSSGSEAIAHAWRQIVMGDADVAVCGGVEGPIEALPIAAFSMMRAMSTRNDEPERASRPFDKDRDGFVFGEAGALMLIETEEHAKARGAKPLARLLGAGITSDAFHMVAPAADGVRAGRAMTRSLELAGLSPADIDHVNAHGTATPIGDAAEANAIRVAGCDQAAVYAPKSALGHSIGAVGALESVLTVLTLRDGVIPPTLNYETPDPEIDLDVVAGEPRYGDYRYAVNNSFGFGGHNVALAFGRY	183.17	gnl|BL_ORD_ID|1968|hsp_num:0	1943			444	1233	isoniazid
BGC0000259.1|Prodigiosin_14 # 19182 # 19496 # 1 # ID=1_14;partial=00;start_type=ATG;rbs_motif=AGG;rbs_spacer=8bp;gc_cont=0.546	BGC0000259.1|Prodigiosin_14 	19182	19496	+	Loose	1000	23.8682	MCR-5.3	35.71	3007282	protein homolog model	n/a	n/a	peptide antibiotic	antibiotic target alteration	MCR phosphoethanolamine transferase	ATGCACATTATCGTCCATAAGATTCGGCTAAAAGACATCGCCCACCGCGCCGCGTTTCGCGACTGGGTGGAGACGACCGATTACCAGGCTTGCCGCCACCTCGACGCGGTACGCGCCTTCGATGTCATCGAAGTCAGCCCTTCGGCGGAGGCGCCGTTTCACTTTATCGAAATCATTCAGCTGAACTCGCTGAAAATGTTCGAGCGCGAGATGCAAACCCCGCTGTTTCAAAGCCTGGTTGAACGCTTTAATCAGTTGGCGGAAGTCGTTGACGAAATCAGCGGAGAACGCATCGCCGATGGTTATCGAGCTTAG	MHIIVHKIRLKDIAHRAAFRDWVETTDYQACRHLDAVRAFDVIEVSPSAEAPFHFIEIIQLNSLKMFEREMQTPLFQSLVERFNQLAEVVDEISGERIADGYRA	MRLSAFITFLKMRPQVRTEFLTLFISLVFTLLCNGVFWNALLAGRDSLTSGTWLMLLCTGLLITGLQWLLLLLVATRWSVKPLLILLAVMTPAAVYFMRNYGVYLDKAMLRNLMETDVREASELLQWRMLPYLLVAAVSVWWIARVRVLRTGWKQAVMMRSACLAGALAMISMGLWPVMDVLIPTLRENKPLRYLITPANYVISGIRVLTEQASSSADEAREVVAADAHRGPQEQGRRPRALVLVVGETVRAANWGLSGYERQTTPELAARDVINFSDVTSCGTDTATSLPCMFSLNGRRDYDERQIRRRESVLHVLNRSDVNILWRDNQSGCKGVCDGLPFENLSSAGHPTLCHGERCLDEILLEGLAEKITTSRSDMLIVLHMLGNHGPAYFQRYPASYRRWSPTCDTTDLSSCSHEALVNTYDNAVLYTDHVLARTIDLLSGIRSHDTALLYVSDHGESLGEKGLYLHGIPYVIAPDEQIKVPMIWWQSSQVYADQACMQTHASRAPVSHDHLFHTLLGMFDVKTAAYTPELDLLATCRKGQPQ	19.01	gnl|BL_ORD_ID|4894|hsp_num:0	5887			1194	1278	colistin A; colistin B
BGC0000259.1|Prodigiosin_15 # 19480 # 20127 # 1 # ID=1_15;partial=00;start_type=ATG;rbs_motif=GGA;rbs_spacer=13bp;gc_cont=0.647	BGC0000259.1|Prodigiosin_15 	19480	20127	+	Loose	700	27.7202	ACC-3	23.17	3001817	protein homolog model	n/a	n/a	monobactam; cephalosporin; penam	antibiotic inactivation	ACC beta-lactamase	ATGGTTATCGAGCTTAGCGTGACGCCGCGTATCGTCATCGCCCTGGGCGGCGCCCACCGCTGCGCCGCCGTTCGGGGATTGCGGCCTCTGTCGGCGGTGAAAAACCTCGCGCGGGCGCAGGCCGTCGCGCTGCTGAACCGGACATGGTGCCAGGGGCACGCGACCGGCTTTACGCTGCGCCATGAGGCGAGTGGACAACCGTTCGGCGAACACCTCCTGCTGGGACGCCGCCACGTTTCCCTCAGCCATTCGCTTGCCTGGTACGCCAGCGCCACCGGCGATATCCCGCTCGGCATCGATCTGCAGCATTATCGCCCCTTCTCCGGCGCGGCGCTGCGCTGGGCCTTTAGCGAGGCGGAACAGCGATTGGGACACATACAGGCCTGCGCCGTCTGGGCCATTCGCGAAGCATTTTTAAAAAGCCACGGCCGCGGTTTGCCCTACGAATTGCGGACGATCGGCATCGACTGGCGCACCGGGTTGGTCTCAAGCGCCGACGGCAGTTTGGCGAGCAGACGCTTCTGGCTGTGGCGCAGCCTGGACTGGACATGCGCACTCTGCTTTCCGGCGGAGGAGAGCATGTCGTTCAGAGCGAACGTTACCGTATTTTCCCTGCCCGCCCCTTCCGCTTTCGGAGCCTTATCATGA	MVIELSVTPRIVIALGGAHRCAAVRGLRPLSAVKNLARAQAVALLNRTWCQGHATGFTLRHEASGQPFGEHLLLGRRHVSLSHSLAWYASATGDIPLGIDLQHYRPFSGAALRWAFSEAEQRLGHIQACAVWAIREAFLKSHGRGLPYELRTIGIDWRTGLVSSADGSLASRRFWLWRSLDWTCALCFPAEESMSFRANVTVFSLPAPSAFGALS	MRKKMQNTLKMLSVITCLALTAQGAMASEMDQAKIKDTVDSLIQPLMQKNNIPGMSVAVTLNGKNYIYNYGLASKQPQQPVTDNTLFEVGSLSKTFAATLASYAQVSGKLSLDKSISHYVPELRGSSFDHISVLNAGTHTTGLALFMPEEVKNTDQLMAYLKAWKPADPAGTHRVYSNIGTGLLGMIAAQSMGMTYEDAIEKTLLPKLGMTHTYLNVPADQAENYAWGYNKKNEPIHVNMEVLGNEAYGIRTNASDLIRYVQANMGQLKLDGNSTLQKALTDTHIGYFKSGKITQDLMWEQLPYPVSLPDLLTGNDMAMTKSVATPIVPPLPPQENVWINKTGSTNGFGAYIAFVPAKKMGIVMLANKNYSIDQRVT	57.03	gnl|BL_ORD_ID|1304|hsp_num:0	1422			126	363	
BGC0000259.1|Prodigiosin_16 # 20568 # 20786 # -1 # ID=1_16;partial=00;start_type=ATG;rbs_motif=AAG;rbs_spacer=5bp;gc_cont=0.598	BGC0000259.1|Prodigiosin_16 	20568	20786	-	Loose	750	21.9422	CMH-2	42.11	3006854	protein homolog model	n/a	n/a	cephalosporin	antibiotic inactivation	CMH beta-lactamase	ATGAAACGCCACTTGAAAGAAGCGCTTGAATGCTGGGGATACCGGGCCAAACAGGTGGTGCAGGTGAAAACCGTCGTCGGTAGGCTGCCGTTCGTTGAAGCGGATGTATTGATAGGTTTCCCGCCAGGCTTGGCGATCCGAGAAATCGAGCGCGGCGTGACGAGCGGTGAGCTGCGCGACCCGACGGCGAGCGCGTTCGTCACCTGCGATACTGAGTGA	MKRHLKEALECWGYRAKQVVQVKTVVGRLPFVEADVLIGFPPGLAIREIERGVTSGELRDPTASAFVTCDTE	MMTKSLSCALLLSVACSAFAAPMSEKQLADVVERTVTPLMKAQAIPGMAVAVIYQGQPHYFTFGKADVAANKPVTPQTLFELGSVSKTFTGVLGGDAIARKEISLADPVTKYWPELTGKQWQGIRLLDLATYTAGGLPLQVPDAVTDNASLLRFYQSWQPKWAPGTTRLYANTSIGLFGSLAVKPSGMRFEEAMTERVFKPLKLNHTWINVPHAEESHYAWGYREGKAVHVSPGMLDAEAYGVKSNVKDMASWVMANMAPETLPQSTLQQGIALAQSRYWRVGAMYQGLGWEMLNWPVDAKTVVDGSDNKVALAPLPVAEVNPPAPPVKASWVHKTGSTGGFGSYVAFIPEKQIGIVMLANKSYPNPVRVETAYRILDALQ	18.90	gnl|BL_ORD_ID|3395|hsp_num:0	4464			636	693	
BGC0000259.1|Prodigiosin_18 # 21291 # 21929 # 1 # ID=1_18;partial=00;start_type=ATG;rbs_motif=AGGA;rbs_spacer=10bp;gc_cont=0.568	BGC0000259.1|Prodigiosin_18 	21291	21929	+	Loose	1000	24.2534	MCR-3.24	50.0	3007265	protein homolog model	n/a	n/a	peptide antibiotic	antibiotic target alteration	MCR phosphoethanolamine transferase	ATGTTCCTGTGGGGGTTCAACGCCATGGGGCCGGTTACCCTGGTCTATTGCTATTTCGGCGAGGGCGATCTGAGCCACAAAGCCCTGATCCTTCTCATGGTCGGCCTGTACCTGCTGCGCATGAACATCGTGCTGACACGTTGGTACGGCAACACCGCCGCGGCCAAACTCAAGGACGTGATGCCCACGCAGCAGGTGCCCTGGCTGGCGGTGATGATGGTCATGATCTTCGGCGGCCTGTACTGCCTGCCCTTTTACTGGGCCAGCCAACTGCAGGGGACGTGGGGCGCGCTGCAATGGCTGGCCATTGGGGTCTACCTGATAGGCACGCTGTTCCACTTCGGCAGCGATTATCAAAAACGGCGCTTCAAACAGGATCCGAACAATAAAGGCCGGTTGCTGAACAGCGGCTTTTGGGGATTGGCGCGCCATCCGAATTATTTCGGCGACTTTCTTATTTTCGTCAGCTTCGGGCTGCTTGCCGGCAACCTGTTTGGCCTGATCGCACCGCTGACTAACCTGGTGCAGTATTTCGCCGACGCCATTCCCAAAAGCGAGAAAATGGCCGAGAAGCGCTACGGCGAGGTCTGGCGCAACTATAAACGTCAGGTTAAGTGTTTCATTCCTTTCGTGCTGTAA	MFLWGFNAMGPVTLVYCYFGEGDLSHKALILLMVGLYLLRMNIVLTRWYGNTAAAKLKDVMPTQQVPWLAVMMVMIFGGLYCLPFYWASQLQGTWGALQWLAIGVYLIGTLFHFGSDYQKRRFKQDPNNKGRLLNSGFWGLARHPNYFGDFLIFVSFGLLAGNLFGLIAPLTNLVQYFADAIPKSEKMAEKRYGEVWRNYKRQVKCFIPFVL	MPSLIKIKIVPLMFFLALYFAFMLNWRGVLHFYEILYKLEDFKFGFAISLPILLVAALNFVFVPFSIRYLIKPFFALLIALSAIVSYTMMKYRVLFDQNMIQNIFETNQNEALAYLSLPIIVWVTIAGFIPAILLFFVEIEYEEKWFKGILTRALSMFASLIVIAVIAALYYQDYVSVGRNNSNLQREIVPANFVNSTVKYVYNRYLAEPIPFTTLGDDAKRDTNQSKPTLMFLVVGETARGKNFSMNGYEKDTNPFTSKSGGVISFNDVRSCGTATAVSVPCMFSNMGRKEFDDNRARNSEGLLDVLQKTGISIFWKENDGGCKGVCDRVPNIEIEPKDHPKFCDKNTCYDEVVLQDLDSEIAQMKGDKLVGFHLIGSHGPTYYKRYPDAHRQFTPDCPRSDIENCTDEELTNTYDNTIRYTDFVIGEMIAKLKTYEDKYNTALLYVSDHGESLGALGLYLHGTPYNFAPDDQTRVPMQVWMSPGFTKEKGVDMACLQQKAADTRYSHDNIFSSVLGIWDVKTSVYEKGLDIFSQCRNVQ	39.19	gnl|BL_ORD_ID|4885|hsp_num:0	5870			1368	1428	colistin A; colistin B
BGC0000259.1|Prodigiosin_19 # 22123 # 24834 # 1 # ID=1_19;partial=00;start_type=ATG;rbs_motif=AAGGA;rbs_spacer=8bp;gc_cont=0.674	BGC0000259.1|Prodigiosin_19 	22123	24834	+	Loose	1280	27.7202	macB	41.67	3000535	protein homolog model	n/a	n/a	macrolide antibiotic	antibiotic efflux	ATP-binding cassette (ABC) antibiotic efflux pump	ATGTCACACACCACTATGCTGGCATTGCAGGGGCTGTCCTGCATGAACTGCGCGCAGCGGGTGAAAAAAGCCCTGGAAAGCCGCAGCGATGTCGAACAGGCGGAGGTTAACGTCCATTACGCCAAAGTGACCGGCGACGCACCGGACAGCGCGCTGATCGACAGCGTGATCGCCGCCGGTTATCAGGCCGAAGTCGCGCCGCACGCCGATACCGAACTGCAGCTGAGCGGCCTGAGCTGCATGCACTGCGTCGGCACCACCCGCAAGGCGCTGGAGGCGGTGCCGGGCGTATTCGCCGCCGACGTCGCTATCGACAGCGCGAAAGTGTATGGCGATGCCGATCCGCAAACGCTGATCGCCGCGGTGGAAGATGCCGGTTATCACGCCAGCGTAGCGGGCGCCGCCGCCCCAAAAACTGAGCCGTTGACTGACGCAACACCTTCGTTGCCGGACGTTCAGCCAGCGGCGCAACCTTCCCTTCCGGCAACCGACAGCGCGGACGACAGCGTACAGCTGCTGCTCAGCGGCATGACCTGCGCCAGCTGCGTCAATAAAGTGCAGTTGGCGCTGCAAAGCGTACCCGGCGTAGAGCACGCGCGCGTCAACCTGGCGGAACGCAGCGCGCTGGTGACCGGCGCCGCCGATGCGCAAGCGCTGGTGGCGGCGGTGGAAAAAGCCGGCTACGGCGCCGAGATGATTCAGGACGAGACCGAACGCCGCGAGCGCCAGCAGCAGACCGCACGCGCCAACATGAAGCGCTTTAGCTGGCAGGCGGCGCTCGGTCTGGCGTTGGGTATCCCGCTGATGGCCTGGGGGCTGTTCGGCGGCAGCATGACGCTGACGCCGGAAACTCAGCGCCCCTGGCTGCTGGTCGGCGTCATCACCCTGGCGGTGATGGTGTTCGCCGGCGGGCACTTCTACCGCAACGCCTGGCGCGCGCTGATGAACGGCAGCGCTACCATGGACACCCTGGTGGCGCTCGGCACCGGCGCCGCCTGGCTTTATTCGATCGCCGTCAACATTTGGCCCGATTTCTTCCCGATGGCGGCGCGCCACCTCTATTACGAGGCCAGCGCGATGATCATCGGTTTGATCAACCTCGGCCATGCGCTGGAGCAACGCGCCCGTCAGCGCTCTTCACAGGCGCTGGAGCGGCTGCTGGATCTGACGCCGCCCACCGCGCGCCTGGTGACCGACGACGGCGAGCGCGATATCCCGCTGGCGGAGGTGCAGCTCGGCATGACGCTGCGGCTGACCACCGGCGATCGCGTGCCGGTCGACGGTGAAATCGAGCAGGGCGAAGTCTGGCTCGATGAAGCGATGCTGACCGGCGAAGCGGTGCCGCAGCAGAAAGGCCCCGGCGATACGGTGCATGCCGGGACGGTGGTCGACGACGGCAGCGTGCTGTTCCGCGCCGCCGCCATCGGCAGCCAAACCACGCTGGCGCGCATCATCAAACTGGTGCGTCAGGCGCAGAGCAGTAAACCGGCGATCGGCCAACTGGCCGACCGCGTCTCGGCGGTGTTCGTGCCGGCGGTGGTGGCGATCGCGCTGTTCAGCGCGGCGATGTGGTACTTCTTCGGCCCGCAGCCGCAGCTGGTCTATACGCTGGTGATCGCCACCACGGTGCTGATCATCGCCTGCCCGTGCGCATTGGGCCTGGCAACGCCGATGTCGATCATCTCCGGCGTCGGCCGCGCGGCGGAGTTCGGCGTGCTGGTGCGCGACGCCGACGCCCTGCAGCAGGCCAGCCAGCTGGACACCCTGGTGTTCGACAAAACCGGCACCCTGACCGAAGGGAAACCGCAGGTGGTGGAGATCCTCACCTTCAATCAGGTCAGCGAACAGCAGGCGATCGGCTGGGCCGCCGCGCTGGAACAAGGCTCCAACCACCCGCTGGCGCGCGCCATCATGGAACGCGCCGCCGGGCAAACGCTGCCGCAGGTAGCGCAGTTCCGCACCCTGCGCGGCGCCGGCGTCAGCGGGGAGATCGACGGCGTTCAGGTGCTGCTGGGCAACGCCGCGCTGCTGGAGCAGCATCAGGTCGCGACCGCCGAACTGGAAGCGCCGATGCGCGCCCAGGCCGAACGCGGCGTGACGCCGGTGCTTCTGGCCGTGGACGGTAAACCGGCCGCGCTGTTCGCCATTCGCGATCCGCTGCACGAGGACAGCGTCGCGGCGCTGCAGCGCCTGCACCAACAGGGGTATCAGTTGGTGATGCTGACCGGCGACAACCCGGTAACCGCCAACGCCATCGCCAAAGAGGCCGGTATCGATCGGGTGATTGCCGGCGTGCTGCCGGACGGCAAAGCGGCGGCGATCAAGCAGCTGCAGGCGCAGGGCCAGCGCGTGGCGATGGTCGGCGACGGCATCAACGACGCCCCGGCGCTGGCGCAGGCCGACGTGGGCATCGCGATGGGCGGCGGCAGCGACATCGCCATCGAGACCGCCGCCATCACCCTGATGCGCCACAGCCTGCACGGCGTGGCGGATGCGGTGGAACTGTCGAAGGCCACGCTGCGCAACATGAAGCAGAACCTGTTCGGCGCCTTTATCTACAATACGCTGGGCATCCCGATCGCCGCCGGCGTGCTCTACCCTCTGACCGGCACGCTGCTCAGCCCGGTGGTGGCGGGCGCGGCGATGGCGCTGTCGTCCATTACCGTGGTCAGCAACGCCAACCGGCTGCTGCGTTTTAAACCCAGGAAATGA	MSHTTMLALQGLSCMNCAQRVKKALESRSDVEQAEVNVHYAKVTGDAPDSALIDSVIAAGYQAEVAPHADTELQLSGLSCMHCVGTTRKALEAVPGVFAADVAIDSAKVYGDADPQTLIAAVEDAGYHASVAGAAAPKTEPLTDATPSLPDVQPAAQPSLPATDSADDSVQLLLSGMTCASCVNKVQLALQSVPGVEHARVNLAERSALVTGAADAQALVAAVEKAGYGAEMIQDETERRERQQQTARANMKRFSWQAALGLALGIPLMAWGLFGGSMTLTPETQRPWLLVGVITLAVMVFAGGHFYRNAWRALMNGSATMDTLVALGTGAAWLYSIAVNIWPDFFPMAARHLYYEASAMIIGLINLGHALEQRARQRSSQALERLLDLTPPTARLVTDDGERDIPLAEVQLGMTLRLTTGDRVPVDGEIEQGEVWLDEAMLTGEAVPQQKGPGDTVHAGTVVDDGSVLFRAAAIGSQTTLARIIKLVRQAQSSKPAIGQLADRVSAVFVPAVVAIALFSAAMWYFFGPQPQLVYTLVIATTVLIIACPCALGLATPMSIISGVGRAAEFGVLVRDADALQQASQLDTLVFDKTGTLTEGKPQVVEILTFNQVSEQQAIGWAAALEQGSNHPLARAIMERAAGQTLPQVAQFRTLRGAGVSGEIDGVQVLLGNAALLEQHQVATAELEAPMRAQAERGVTPVLLAVDGKPAALFAIRDPLHEDSVAALQRLHQQGYQLVMLTGDNPVTANAIAKEAGIDRVIAGVLPDGKAAAIKQLQAQGQRVAMVGDGINDAPALAQADVGIAMGGGSDIAIETAAITLMRHSLHGVADAVELSKATLRNMKQNLFGAFIYNTLGIPIAAGVLYPLTGTLLSPVVAGAAMALSSITVVSNANRLLRFKPRK	MSLIECKNINRYFGSGENRVHILKDISLSIEKGDFVAIIGQSGSGKSTLMNILGCLDTAGSGSYRIDGIETAKMQPDELAALRRERFGFIFQRYNLLSSLTARDNVALPAVYMGMGGKERSARADKLLQDLGLASKEGNKPGELSGGQQQRVSIARALMNGGEIIFADEPTGALDTASGKNVMEIIRRLHEAGHTVIMVTHDPGIAANANRVIEIRDGEIISDTSKNPEIPASNVGRIQEKASWSFYYDQFVEAFRMSVQAVLAHKMRSLLTMLGIIIGIASVVSVVALGNGSQKKILEDISSMGTNTISIFPGRGFGDRRSGKIKTLTIDDAKIIAKQSYVASATPMTSSGGTLTYRNTDLTASLYGVGEQYFDVRGLKLETGRLFDENDVKEDAQVVVIDQNVKDKLFADSDPLGKTILFRKRPLTVIGVMKKDENAFGNSDVLMLWSPYTTVMHQITGESHTNSITVKIKDNANTRVAEKGLAELLKARHGTEDFFMNNSDSIRQMVESTTGTMKLLISSIALISLVVGGIGVMNIMLVSVTERTKEIGIRMAIGARRGNILQQFLIEAVLICIIGGLVGVGLSAAVSLVFNHFVTDFPMDISAASVIGAVACSTGIGIAFGFMPANKAAKLNPIDALAQD	140.22	gnl|BL_ORD_ID|446|hsp_num:0	487			555	627	erythromycin
